This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Flamel Technologies Announces Three New Partnership Agreements; Second Quarter 2010 Results

Flamel Technologies (Nasdaq:FLML) today announced three new partnership agreements and its financial results for the second quarter of 2010. Highlights included:

  • Three new agreements with two pharmaceutical partners:
    • Two agreements with a single partner involve the Micropump platform;
    • A third agreement for the development of a controlled release formulation involving a peptide and a protein intended to treat metabolic disease
  • Positive advances in the Company’s work with Pfizer and Merck Serono; and
  • Positive cash-flow at constant-currency rates.

“Flamel continued to advance on development programs this quarter with our existing partners, while adding new projects into our feasibility pipeline. All of our projects involving existing molecules continue to progress through pre-clinical and clinical development. The already-marketed molecules on which we are working to develop improved formulations with partners, together with competitors within their respective classes, represented over $17 billion in revenues in 2009,” commented Stephen H. Willard, Flamel’s chief executive officer. “In addition, we believe that the applicability of the Medusa platform in creating better formulations of biologics will continue to gain considerable traction within the industry as our data become available.”

Financial Results

Flamel reported total revenues in the second quarter 2010 of $7.5 million, compared to $9.6 million in the year-ago period. License and research revenues were $3.3 million versus $4.3 million in the second quarter of 2009. Product sales and services in the current quarter totaled $1.9 million versus $2.5 million in the second quarter of 2009. Other revenues during the current quarter, including royalties on the sale of Coreg CR™, were $2.4 million versus $2.7 million in the year-ago period.

Costs and expenses during the second quarter of 2010 were $(12.2) million versus $(13.2) million in the year-ago period. Costs of goods and services sold in the quarter totaled $(1.6) million versus $(1.9) million in the second quarter of 2009. Research and development expenses were $(7.9) million versus $(8.0) million in the second quarter of 2009. SG&A declined to $(2.8) million from $(3.3) million in the year-ago period.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs